Reporting on IPRs protection issues by biopharmaceutical companies Online publication date: Mon, 14-Oct-2019
by Joanna Dyczkowska; Ricardo Luiz Sichel
International Journal of Intellectual Property Management (IJIPM), Vol. 9, No. 3/4, 2019
Abstract: Due to quick development of proprietary methodologies, systems or technologies pharmaceuticals and biotechnology industry requires a variety of IPRs protection mechanisms. Going forward, the complex R&D projects and their long-term character impose a necessity of transparency concerning IPRs protection. Stakeholders should not be provided with a misleading impression about the protection breadth, the likelihood of patent grant or the ability of the company to enforce its patent rights. The paper explores and analyses the critical IPRs protection issues disclosed by European biopharmaceutical companies in the narrative parts of their annual reports. These critical issues refer to IPRs protection strategy, risk and mitigation policies, R&D and IPRs regulatory framework, patent portfolio, infringements or litigations, and exclusive rights. The examination of disclosure practices proved that the IPRs protection-related risks and exclusive rights were the most frequently reported areas.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook